#USA #Washington #Living Donor #Kidney Patients #AAKP

Advocating for Kidney Patients: Engaging Congress During the Summer Recess

The rising wave of advocacy concerning kidney health reached new heights as the American Association of Kidney Patients (AAKP), the leading non-partisan advocacy group for kidney patients in the U.S., embarked on its second annual campaign titled All Kidney Policy is Local™. This event, held during the Congressional summer recess, empowers kidney patients, their families, living donors, and care partners across the nation to connect directly with their Congressional representatives. It emphasizes the importance of personal stories and real-life impacts of health policies, fostering a crucial dialogue on matters that significantly affect patients' lives.

Since the campaign's inception in 2025, kidney patient advocates have engaged in more than 300 targeted meetings with members of both the U.S. House of Representatives and the Senate. This grassroots initiative, which spans from Maine to Washington state, aims to fortify the relationship between kidney health advocates and their elected officials, thereby allowing patients to play a more active role in shaping healthcare policies that affect them.

AAKP President Edward V. Hickey, III, a chronic kidney disease patient himself, expressed the importance of this advocacy. He stated, "Kidney patients and organ donors are not passive participants in healthcare nor in the decisions that affect their ability to work and provide for their families. They are informed, engaged citizens and a powerful voting constituency."

Hickey, who is also a U.S. Marine Corps veteran and has served across various roles in presidential administrations, points out that decisions made in Washington bear direct consequences on local communities, highlighting the vital need for patient advocacy at the federal level.

The campaign predominantly raised critical concerns including the immediate passage of the Living Donor Protection Act (LDPA), legislation designed to safeguard living organ donors from discrimination related to insurance and employment. Co-sponsored by Senators Tom Cotton (R-AK) and Kirsten Gillibrand (D-NY), this bipartisan bill also received strong support from numerous other Congressional figures. Notably, the campaign addressed the alarming decline in living donor rates, urging prompt legislative action.

Moreover, there was a strong call for reforming the U.S. Preventive Services Task Force (USPSTF) to better serve kidney health needs. For nearly two decades, the USPSTF has been criticized for its lack of kidney expertise and an unresponsive approach to stakeholders’ requests. AAKP advocates argue that an overhaul is essential to ensure effective disease screening recommendations and patient care, as early detection can dramatically alter treatment outcomes and improve patients' quality of life.

Further discussions during the summer meetings revolved around establishing a modern, patient-centered Medicare payment system for kidney care, seeking to replace the outdated bundled payment system currently in place. This system, largely designed for earlier healthcare models, does not effectively incorporate the rapid advancements in kidney science and patient care, hindering access to innovative treatments and improving patient outcomes.

The advocacy team's concerns also included holding the FDA accountable for its slow decision-making in approving next-generation transplant drugs. The current standard immunosuppressive drugs have not evolved significantly in two decades, presenting several side effects and risks for patients. AAKP underscored the urgency of approving new clinical endpoints that would facilitate the development and accessibility of safer kidney transplant drugs.

In addition to individual legislative issues, the AAKP discussed broader strategies aimed at enhancing Congressional appropriations for kidney research and science. The goal is to expand these investments by up to $1.8 billion, supporting initiatives through the National Institutes of Health and the U.S. Department of Defense. This critical funding is seen as essential to fostering life-saving innovations in kidney health.

Paul T. Conway, AAKP Vice President, highlighted the significance of personalizing policy concerns through direct interactions with Congressional leaders. By sharing patient perspectives and advocating for sustained federal investment in kidney research, AAKP aims to ensure the U.S. remains a leader in kidney health advancements.

AAKP also provides training in advocacy skills and social media engagement for patients and organ donors, working to empower individuals within the kidney community. The network encourages a collective voice that not only advances kidney research and disease awareness but also combats federal regulations detrimental to patient care. Regular engagements with Congressional committees help AAKP maintain a prominent presence in discussions surrounding kidney health policy.

To support kidney advocacy efforts, AAKP encourages continued engagement with patient communities. The powerful stories and experiences shared during the All Kidney Policy is Local™ campaign not only influence health policy but also build a stronger, united front for kidney patients seeking to improve their quality of life and treatment outcomes. Follow AAKP on social media to stay updated on advocacy initiatives and patient support efforts.